Creative Biolabs Advances Antibody-Drug Conjugate Technology with Innovative Engineering Techniques
Creative Biolabs has made significant breakthroughs in antibody-drug conjugate (ADC) development, demonstrating advanced glycosylation engineering and innovative approaches to targeting cancer treatments through bispecific and antibody-oligonucleotide conjugates.
